Denali Therapeutics Inc.
Sembol: DNLI
NASDAQ
20.86
USDBugünkü piyasa fiyatı
-14.6980
F/K Oranı
-0.2609
PEG Oranı
2.88B
MRK Kapağı
- 0.00%
DIV Verimi
Denali Therapeutics Inc. (DNLI) Finansal Tablolar
Bilanço
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4623.21 | 1034.5 | 1336.2 | 865.4 | |||||||||
balance-sheet.row.short-term-investments | 4147.99 | 907.4 | 1118.2 | 571.9 | |||||||||
balance-sheet.row.net-receivables | 9.3 | 2.7 | 5 | 1.2 | |||||||||
balance-sheet.row.inventory | -6.6 | 0 | -5 | 0 | |||||||||
balance-sheet.row.other-current-assets | 130.34 | 26.9 | 36.1 | 30.6 | |||||||||
balance-sheet.row.total-current-assets | 4756.24 | 1064.1 | 1372.3 | 897.2 | |||||||||
balance-sheet.row.property-plant-equipment-net | 283.89 | 71.6 | 74.5 | 69.6 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-investments | 12.61 | 1.6 | 1.5 | 425.4 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 53.03 | 16.5 | 11.9 | 11.9 | |||||||||
balance-sheet.row.total-non-current-assets | 349.53 | 89.8 | 87.9 | 506.9 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 5105.77 | 1153.9 | 1460.2 | 1404.2 | |||||||||
balance-sheet.row.account-payables | 21.4 | 9.5 | 2.8 | 4.8 | |||||||||
balance-sheet.row.short-term-debt | 27.59 | 7.3 | 7.3 | 5.5 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 191.16 | 45 | 53 | 58.6 | |||||||||
Deferred Revenue Non Current | 1.05 | 0 | 0.5 | 4.7 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 270.01 | 61.2 | 63.8 | 47.7 | |||||||||
balance-sheet.row.total-non-current-liabilities | 193.36 | 45 | 53.9 | 63.6 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 211.49 | 45 | 60.4 | 58.6 | |||||||||
balance-sheet.row.total-liab | 802.96 | 123 | 417.8 | 441.9 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 6.81 | 1.7 | 1.7 | 1.5 | |||||||||
balance-sheet.row.retained-earnings | -4091.1 | -1116.2 | -971 | -645 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -3.97 | 0.6 | -6.9 | -2.5 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 8391.07 | 2144.8 | 2018.6 | 1608.2 | |||||||||
balance-sheet.row.total-stockholders-equity | 4302.82 | 1031 | 1042.4 | 962.3 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 5105.77 | 1153.9 | 1460.2 | 1404.2 | |||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-equity | 4302.82 | 1031 | 1042.4 | 962.3 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 5105.77 | - | - | - | |||||||||
Total Investments | 4157.49 | 909 | 1118.2 | 997.4 | |||||||||
balance-sheet.row.total-debt | 218.75 | 52.2 | 60.4 | 58.6 | |||||||||
balance-sheet.row.net-debt | -256.47 | -74.9 | -157.7 | -234.9 |
Nakit Akış Tablosu
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -145.22 | -145.2 | -326 | -290.6 | |||||||||
cash-flows.row.depreciation-and-amortization | 16.73 | 16.7 | 10.4 | 8.6 | |||||||||
cash-flows.row.deferred-income-tax | -56.28 | -2.4 | 0 | 8.7 | |||||||||
cash-flows.row.stock-based-compensation | 108.1 | 108.1 | 99.8 | 85.2 | |||||||||
cash-flows.row.change-in-working-capital | -289.93 | -289.9 | -24 | -20.4 | |||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.account-payables | 2.43 | 2.4 | 2.3 | 3.7 | |||||||||
cash-flows.row.other-working-capital | -292.36 | -292.4 | -26.3 | -24.1 | |||||||||
cash-flows.row.other-non-cash-items | 8.61 | -45.2 | -4.9 | -3 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -357.99 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -12.94 | -12.9 | -17.8 | -8.5 | |||||||||
cash-flows.row.acquisitions-net | -262.25 | 0 | 123.6 | 13.1 | |||||||||
cash-flows.row.purchases-of-investments | -1813.7 | -1813.7 | -1115 | -1422.9 | |||||||||
cash-flows.row.sales-maturities-of-investments | 2075.95 | 2075.9 | 991.5 | 1409.8 | |||||||||
cash-flows.row.other-investing-activites | 262.25 | 0 | -123.6 | -13.1 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 249.31 | 249.3 | -141.4 | -21.6 | |||||||||
cash-flows.row.debt-repayment | 0 | 0 | -3.1 | -3.7 | |||||||||
cash-flows.row.common-stock-issued | 17.82 | 17.8 | 296.2 | 19.3 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-financing-activites | 17.82 | 17.8 | 17.6 | 3.7 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 17.82 | 17.8 | 310.7 | 19.3 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | -90.86 | -90.9 | -75.4 | -213.7 | |||||||||
cash-flows.row.cash-at-end-of-period | 479.87 | 127.1 | 219.5 | 295 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 570.73 | 218 | 295 | 508.6 | |||||||||
cash-flows.row.operating-cash-flow | -357.99 | -358 | -244.7 | -211.4 | |||||||||
cash-flows.row.capital-expenditure | -12.94 | -12.9 | -17.8 | -8.5 | |||||||||
cash-flows.row.free-cash-flow | -370.93 | -370.9 | -262.5 | -219.9 |
Gelir Tablosu Satırı
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 330.53 | 330.5 | 108.5 | 48.7 | |||||||||
income-statement-row.row.cost-of-revenue | 14.92 | 16.7 | 7 | 5.6 | |||||||||
income-statement-row.row.gross-profit | 315.61 | 313.8 | 101.4 | 43.1 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 423.88 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 103.35 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -2.18 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.operating-expenses | 525.05 | 510.5 | 449.2 | 344.4 | |||||||||
income-statement-row.row.cost-and-expenses | 527.23 | 527.2 | 449.2 | 344.4 | |||||||||
income-statement-row.row.interest-income | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.interest-expense | -21.08 | 0 | 14.8 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -2.18 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.total-operating-expenses | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.interest-expense | -21.08 | 0 | 14.8 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 16.73 | 16.7 | 10.4 | 8.6 | |||||||||
income-statement-row.row.ebitda-caps | -192.31 | - | - | - | |||||||||
income-statement-row.row.operating-income | -196.7 | -196.7 | -340.7 | -295.8 | |||||||||
income-statement-row.row.income-before-tax | -145.19 | -145.2 | -326 | -291.2 | |||||||||
income-statement-row.row.income-tax-expense | -12.3 | 0 | 0 | -0.6 | |||||||||
income-statement-row.row.net-income | -145.22 | -145.2 | -326 | -290.6 |
Sıkça Sorulan Sorular
Nedir Denali Therapeutics Inc. (DNLI) toplam varlıklar?
Denali Therapeutics Inc. (DNLI) toplam varlıklar 1153917000.000 şeklindedir.
İşletmenin yıllık geliri nedir?
Yıllık gelir 1267000.000'dur.
Firma kâr marjı nedir?
Firma kar marjı 0.955'dir.
Şirket serbest nakit akışı nedir?
Serbest nakit akışı -2.683'dur.
İşletme net kar marjı nedir?
Net kâr marjı -0.439'dir.
Firma toplam geliri nedir?
Toplam gelir -0.595'dur.
Nedir Denali Therapeutics Inc. (DNLI) net kar (net gelir)?
Net kar (net gelir) -145224000.000'dur.
Firmanın toplam borcu nedir?
Toplam borç 52241000.000'dir.
Faaliyet giderleri rakamı nedir?
İşletme giderleri 510504000.000'dır.
Şirket nakit rakamı nedir?
İşletme içi nakit 127106000.000'tir.